Results 71 to 80 of about 6,309 (194)

First‐Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real‐World Insights From a German Single‐Referral Center

European Journal of Neurology, Volume 33, Issue 2, February 2026.
Real‐world long‐term treatment with the first‐generation TTR silencers, patisiran and inotersen, in patients with ATTRv‐PN is safe, consistently reducing serum TTR levels, stabilizing neurologic symptoms, cardiac and renal functions, and nutritional parameters.
Marilin S. Koch, Fabian aus dem Siepen, Ute Hegenbart, Stefan Schönland, Markus Weiler   +4 more
wiley   +1 more source

Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report

Journal of International Medical Research, 2022
Cardiac amyloidosis usually presents with diastolic dysfunction, but sometimes systolic dysfunction develops, particularly at its advanced stage. However, the therapeutic strategy for patients with cardiac amyloidosis and systolic dysfunction remains ...
Teruhiko Imamura, Toshihide Izumida, Masakazu Hori, Shuhei Tanaka, Koichiro Kinugawa   +4 more
doaj   +1 more source

Navigating the Lead Paradox: Successful Co‐Implantation of Cardiac Contractility Modulation Device and a Micra Leadless Pacemaker

Journal of Cardiovascular Electrophysiology, Volume 37, Issue 2, Page 434-437, February 2026.
This central illustration visually summarizes the first co‐implantation of a Cardiac Contractility Modulation (CCM) system and a Micra leadless pacemaker in a 78‐year‐old male with wild‐type transthyretin cardiac amyloidosis and NYHA Class III heart failure.
Gabriele Pavani, Paolo Garrone, Gianpaolo Varalda, Antonino Previti, Matteo Bianco, Alessandra Chinaglia   +5 more
wiley   +1 more source

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Orphanet Journal of Rare Diseases, 2018
Background Emerging evidence suggests that several factors can impact disease progression in transthyretin amyloid polyneuropathy (ATTR-PN). The present analysis used longitudinal data from Val30Met patients participating in the tafamidis (selective TTR ...
Leslie Amass, Huihua Li, Balarama K. Gundapaneni, Jeffrey H. Schwartz, Denis J. Keohane   +4 more
doaj   +1 more source

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin

ESC Heart Failure, 2023
Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy ...
Stephan Dobner, Benedikt Bernhard, Babken Asatryan, Stephan Windecker, Stefan Stortecky, Thomas Pilgrim, Christoph Gräni, Lukas Hunziker   +7 more
doaj   +1 more source

Long-term Negative Psychological Impact of Presymptomatic Testing on Familial Amyloid Polyneuropathy: Efecto psicológico negativo a largo plazo de las pruebas genéticas presintomáticas en la polineuropatía amiloide familiar [PDF]

, 2019
http://sherpa.ac.uk/romeo/search.php?issn=2174-0550This study addresses the profile of at-risk subjects whose long-term psychological impact of presymptomatic testing (PST) for Familial Amyloid Polyneuropathy (FAP) TTR V30M is negative.
Dinis, Maria Alzira Pimenta, Gomes, Ana I. Pinheiro, Leite, Ângela M. Teixeira, Pinto, Ana M. Baldaia Carvalho, Pinto, Susana M. Lêdo da Silva   +4 more
core   +3 more sources

Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non‐Diabetic Patient With Cardiac Amyloidosis

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Dapagliflozin, though beneficial in heart failure, can rarely cause euglycemic ketoacidosis even in non‐diabetic patients. Clinicians should maintain a high index of suspicion for metabolic acidosis in patients on SGLT2 inhibitors presenting with unexplained illness, regardless of blood glucose level.
Salhamoud Abdelfatah Saleh Hamoud, Ellie Harding   +1 more
wiley   +1 more source

Small molecule probes of protein aggregation [PDF]

, 2017
Understanding the mechanisms of amyloid formation and toxicity remain major challenges. Whilst substantial progress has been made in the development of methods able to identify the species formed during self-assembly and to describe the kinetic ...
Abedini, Abskharon, Acerra, Aitken, Alison E Ashcroft, Ambadipudi, Andreetto, Arosio, Arosio, Arosio, Baell, Baell, Balchin, Baldwin, Baranczak, Barrera-Ocampo, Beck, Bernstein, Bieschke, Blazer, Bleem, Bu, Bucciantini, Bulawa, Butler, Cao, Caughey, Cegelski, Cheng, Cheruvara, Chiti, Coelho, Cohen, Cohen, Collinge, Cremades, Doig, Domanska, Eisele, Emamzadeh, Ferreira, Ferreira, Fessel, Foit, Fulop, Gao, Gelman, Goodman, Gopalakrishnan, Habchi, Habchi, Hampel, Heller, Hoffner, Horrocks, Iljina, Jahn, Jakhria, Jiang, Jimenez, Johnson, Joshi, Joshi, Julian, Karamanos, Karamanos, Kelly, Klabunde, Knaus, Konijnenberg, Kotler, Krotee, Kulikov, Kumar, Kumar, Laganowsky, Landreh, Lashuel, Lashuel, Lee, Lee, Lindberg, Liu, Liu, Liu, Lorenzo, Lydia M Young, Mankad, Mauran, McWilliams-Koeppen, Mehta, Meng, Mogk, Mukherjee, Muyldermans, Nicoll, Nillegoda, Noormägi, Oskarsson, Palhano, Poli, Porat, Qiang, Ruan, Saelices, Sap, Saraogi, Saunders, Sawkar, Scarff, Scarpioni, Schormann, Seither, Sexton, Sheena E Radford, Sievers, Sipe, Sivanesam, Song, Sormanni, Spencer, Sun, Sweeney, Tipping, Tipping, Tomiyama, Truex, Turoverov, Tyedmers, Valleix, van Bockstaele, Whittingham, Wisniewski, Woerner, Yan, Young, Young, Young, Young, Zumbo   +139 more
core   +1 more source

Tafamidis for transthyretin familial amyloid polyneuropathy [PDF]

Neurology, 2012
To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP).In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo. Coprimary endpoints were the Neuropathy Impairment Score-Lower Limbs (NIS-LL) responder analysis (
Teresa Coelho, Luis F. Maia, Ana Martins da Silva, Marcia Waddington Cruz, Violaine Planté-Bordeneuve, Pierre Lozeron, Ole B. Suhr, Josep M. Campistol, Isabel Maria Conceição, Hartmut H.-J. Schmidt, Pedro Trigo, Jeffery W. Kelly, Richard Labaudinière, Jason Chan, Jeff Packman, Amy Wilson, Donna R. Grogan, Oscar C Imventarza, Pablo J Wainberg, Lucas M Berra, Henryk Maultasch, Jaime Gold, Juan Carlos Pare Bardera, Andree Zibert   +23 more
openaire   +2 more sources

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo, Giuliano Cassataro, Stefano Ministrini, Simon F. Stämpfli   +3 more
wiley   +1 more source